New Drug May Overcome Treatment Resistance in a High-risk Children’s Cancer
Published on
CHOP researchers have identified a powerful new drug with “unparalleled” strength against refractory types of neuroblastoma.
Published on
CHOP researchers have identified a powerful new drug with “unparalleled” strength against refractory types of neuroblastoma.
Published on
The Division of Genomic Diagnostics at CHOP has launched a series of hereditary and somatic cancer gene panels to facilitate a precision medicine approach to cancer diagnostics.
Published on
A $1.5 million grant to CHOP from Alex’s Lemonade Stand Foundation supports an innovative treatment for children with high-risk neuroblastoma.
Published on
The brain tumor research team at The Children’s Hospital of Philadelphia continues its commitment to providing as much data as possible to as many brilliant minds as possible with the expansion of its tumor bank and advances in data sharing.
Published on
CHOP’s Dr. John Maris comments on a just-published major study of genes that raise a child’s risk for cancer, and what this means for counseling families and patients.
Published on
A collaborative effort transformed the proton therapy facility into colorful rooms with unique themes and helped replace patients’ anxiety with anticipation.
Published on
CHOP pediatric oncology researchers have pinpointed a crucial change in a single DNA “letter” that predisposes children to an aggressive form of neuroblastoma.
Published on
The Four Seasons Parkway Run & Walk raised over $1 million and proceeds support research and survivorship programs at CHOP’s Cancer Center.
Published on
CHOP and four other high-profile oncology research programs recently formed the Pediatric Preclinical Testing Consortium to test new cancer treatments for children.
Published on
Building on its decades-long investigations in the biology and treatment of neuroblastoma, CHOP will lead the consortium’s neuroblastoma research program.